You are subscribed to one of the following page update alerts:
Vaccine Code Set Update Publication Date: February 14, 2022
The individual filenames included in this distribution contain the publication date (20220214)
Release Notes: This release includes updates for all vaccine codes except core Vaccine Information Statement (VIS) codes. In addition, the COVID-19 US Vaccine Codes table has been updated to reflect changes in this release. IIS COVID-19 Vaccine Related Code | CDC
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
General Note Regarding This Release: Codes with “Last Update” dates from January 26, 2022 through February 14, 2022 reflect the changes and additions in this release.
Important note for this release: All NDC Units of Use and Units of Sale with a last update date of 1/31/2022 reflect a technical change in the files received from the FDA, which updated the date but did not change any other fields on the CDC published code set files.
This release includes the following code set updates:
Vaccine Code Set Updates Not Related to COVID-19
- QUADRACEL New Presentation NDCs
- PREHEVBRIO CVX Code and NDC Description Updates
- NDCs Previously Retired on the FDA Files Reactivated in this Release
- CVX to Vaccine Group Correction
COVID-19 Related Code Updates
- Pfizer-BioNTech Vaccine Code Updates
- Moderna Vaccine Code Updates
Vaccine Code Set Updates Not Related to COVID-19
- QUADRACEL New Presentation NDCs for Pre-filled Syringes:
Table 1: New Quadracel NDCs and Maps
New NDC Codes | Codes and Maps |
|---|
NDC Unit of Sale: NDC Unit of Use: | MVX = PMC “Sanofi Pasteur”
CVX = 130 “Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated” |
|---|
- PREHEVBRIO CVX Code and NDC Description Updates:
- CVX Code 220 Descriptions modified to add “3-antigen” for further differentiation:
Long Description: “Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted”
Short Description: “HepB recombinant, 3-antigen, Al(OH)3”
- NDC Generic Descriptions for NDC Unit of Use 75052-001-01 and NDC Unit of Sale 75052-001-10 also modified:
“Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted”
- NDCs Previously Retired on the FDA Files Reactivated in this Release:
Table 2: NDC Pairs Reactivated – End Date of 12/31/2021 Removed
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 |
|---|
PedvaxHIB | Merck Sharp & Dohme Corp. | 00006-4897-00 | 00006-4897-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4981-00 | 00006-4981-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4995-41 | 00006-4995-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4094-02 | 00006-4094-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4995-00 | 00006-4995-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4094-09 | 00006-4094-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4093-09 | 00006-4093-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4992-00 | 00006-4992-01 |
|---|
RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 00006-4093-02 | 00006-4093-01 |
|---|
VAQTA | Merck Sharp & Dohme Corp. | 00006-4095-02 | 00006-4095-01 |
|---|
VAQTA | Merck Sharp & Dohme Corp. | 00006-4841-41 | 00006-4841-01 |
|---|
VAQTA | Merck Sharp & Dohme Corp. | 00006-4841-00 | 00006-4841-01 |
|---|
VAQTA | Merck Sharp & Dohme Corp. | 00006-4096-02 | 00006-4096-01 |
|---|
VAQTA | Merck Sharp & Dohme Corp. | 00006-4831-41 | 00006-4831-01 |
|---|
- CVX to Vaccine Group Correction
- CVX Code 35 “tetanus toxoid, adsorbed” is now associated to Vaccine Group “Td”
This is an inactive CVX code associated to historic inactive NDCs. In a review of records, it was found to have never been associated to any Vaccine Group.
COVID-19 Related Code Updates
- Pfizer-BioNTech COVID-19 Vaccine Code Updates
- CPT to CVX Code Map Added:
- CPT Code 91308 “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use”
Mapped to
- CVX 219 “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation”
- BLA licensed COMIRNATY labeled NDCs added for 30 mcg/0.3 mL for adult 16+ adult tris-sucrose formulation, GREY CAP (Note: These NDCs are not yet orderable)
Table 3: New NDCs and associated codes for the Pfizer-BioNTech COMIRNATY labeled product
Unit of Sale | Unit of Use | CVX | MVX | CPT |
|---|
0069-2025-10 | CARTON, 10 MULTI-DOSE VIALS | 0069-2025-01 | VIAL, 2 mL, MULTI-DOSE VIAL | 217 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | PFR | 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
0069-2025-25 | CARTON, 25 MULTI-DOSE VIALS |
|---|
- Moderna COVID-19 Vaccine Code Updates
- New 2.5 mL vial 50 mcg/0.50 mL for booster only, adult 18+, DARK BLUE CAP, new concentration and booster dose volume. Pending potential FDA EUA authorization. New CVX added, CPT code not yet available.
Table 4: New NDCs and CVX Code associated to the Moderna new 2.5 mL vial presentation
New Unit of Sale | New Unit of Use | New CVX | MVX | CPT |
|---|
80777-275-99 | CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH | 80777-275-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | 221 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | MOD | NA | NA |
|---|
- Moderna CVX Code 207 description updated to better differentiate that code from the new code 221. Added dose volumes: “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose”
